Back to news

NRx Pharmaceuticals (Nasdaq: NRXP) Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Globe Newswire•17/11/2026•07:18 ET
0

Key Highlights

  • ➤FDA approved preservative-free ketamine ahead of November 10 GDUFA goal date
  • ➤NRx began commercial sales with a 17-person sales force and first order received
  • ➤DARPA awarded NRx Defense Systems an $11.25 million prime contract
  • ➤Q3 net patient service revenue $1.2M, up from $0.2M year over year
  • ➤Q3 net loss $2.2M, or $0.05 per share, versus $5.9M loss

Expert Statements

Jonathan Javitt, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals

“The third quarter and the weeks since have marked NRx’s transition from a development-stage company to a commercial one”

Jonathan Javitt, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals

“FDA approval of preservative-free ketamine is our first drug approval and the first for our blow-fill-seal luer-lock platform, which we believe can deliver sterile injectable products made in the United States at a fraction of the cost of glass and at net margins that rival those of innovative products.”

Jonathan Javitt, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals

“Our 17-person veteran sales force is in the field and we have received our first order.”

Jonathan Javitt, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals

“Each of our divisions is advancing: we aim to submit a rolling NDA for NRX-100 by year-end, with our new Yale collaboration supporting the Accelerated Approval pathway; we are introducing NRX-200 for subcutaneous ketamine delivery; and our DARPA-funded SPARC-TMS program is moving forward.”

Jonathan Javitt, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals

“Our goal for 2027 is to build a commercially successful company that demonstrates profitability, while funding our innovation through non-dilutive sources wherever possible.”

FDA approved the Company’s first drug, preservative-free ketamine, ahead of its GDUFA goal date; commercial launch underway with a 17-person sales force

New Yale University collaboration supports the Accelerated Approval pathway for NRX-100; new pipeline product NRX-200 announced for subcutaneous ketamine

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in